Category Archives: Food Supplements

A hectic lifestyle, result of longer and more demanding work days and work life, is leading to consumers shift preferences in terms of plugging the dietary gaps. While it is a logical outcome of this lifestyle that more and more people have no time to prepare elaborate meals, packed with nutrition, it is also true that awareness regarding the same is leading to hustle for capsule health.

What this means is that people are looking for easy to eat, smaller portions of food, which are as healthy as it can get. And, thus, it comes as no surprise that there is demand for on-the-go nutrition which players in theprobiotic ingredients marketare taking head on.

As per a study done by Transparency Market Research study, the global probiotic ingredients is set to chart a decent CAGR (Compound Annual Growth Rate) of over 6% between 2019 and 2027, helping the market reach a worth of USD 7400 mn by the end of the forecast period.

Request A Sample https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=57333

Gut Health Taking Centre stage; Leading to Growth in Probiotic Ingredients Market

The market will see the stated growth trajectory owing to growing scientific validation and approvals on products related to gut health. Considering that 70% of immune system is managed by the digestive tract, it is critical to maintain the health of this region in order to life a wholesome life. It is also worth noting here that the most commonly used bacteria strains in the market include lactobacilli and bifidobacteria.

It is noteworthy here that this need to maintain good gut health is generating demand for dietary supplements in pharmaceuticals, driving demand for probiotic ingredients.

Explore Transparency Market ResearchS Award-Winning Coverage of the Global Industry @https://www.prnewswire.com/news-releases/coconut-syrup-market-to-reach-valuation-of-us-354-mn-by-2029-demand-for-organic-food-in-us-shall-propel-the-dominance-of-north-america-in-global-market-finds-tmr-301027365.html

Forecast Period to Witness a Consolidated Competitive Landscape of Global Probiotic Ingredients Market

The market landscape is only slightly consolidated but competitive and players collaborate and partner in order to maintain a fair frasp on the market share. Some of the most prominent names in the market landscape include Kerry (Ireland), DowDuPont (US), CHR. Hansen (Denmark), Biogaia (Sweden), Probi (Sweden),Glac Biotech (Taiwan), Bifodan (Denmark), Lallemand (Canada), UAS Laboratories (US), and Biena (US), among others. It is notable that 70% of the market share is held by three companies CHR Hansen, DowDuPont, Lallemand and Kerry.

Request for Covid-19 Impact Analysis @https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=57333

Asia Pacific to Show High Growth Numbers of the Forecast Period

Owing to a predisposition for taking supplements, the APAC (Asia Pacific) region is set to chart a high CAGR over the forecast period. Countries that will contribute massively to the growth include China, India, and Japan. The growth is attributable to rising awareness in the region too as far as prevention of disorders relating to lifestyle choices is concerned.

Read more here:

Probiotic Ingredients in Dietary Supplements | Covid-19 Impact | Industry Business Outlook, Revenue, Trends and Forecasts to 2027 - KSU | The Sentinel...

Gut health supplements market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow at a CAGR of 7.50% in the above-mentioned forecast period. Rising demand for nutritional and fortifying food additives drives the gut health supplements market.

The report titledGut health supplements Market : Size, Trends and Forecasts (2021-2026), delivers an in-depth analysis of the Gut health supplements Market by value, by production capacity, by companies, by applications, by segments, by region, etc.

The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the Gut health supplementsindustry. Growth of the overall Gut health supplementsmarket has also been forecasted for the period 2021-2027, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Complete study compiled with over 100+ pages, list of tables & figures, profiling 10+ companies. Ask for Sample (High Priority to corporate email id) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gut-health-supplements-market

Competitive Analysis: Global Gut health supplements market

The major players covered in the gut health supplements market report are DSM, Bayer AG, Beneo-Orafti, GTC Nutrition, Amano Enzyme, Speciality Enzymes & Biochemicals CO, National Enzyme Co., GalaxoSmithKline Plc, Amway Corp., Abbott Laboratories, Yakult Honsha Co. Ltd., Dabur India Ltd., Nestle SA, Douglas Laboratories Canada Incorporation, Pfizer Inc., Cargill, Incorporated, Nebraska Cultures Inc. other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analyst understands competitive strengths and provides competitive analysis for each competitor separately.

Impact of COVID-19:

Gut health supplements Market report analyses the impact of Coronavirus (COVID-19) on the Gut health supplements industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Gut health supplements market in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Click to View Full Report TOC, figure and tables: https://www.databridgemarketresearch.com/toc/?dbmr=global-gut-health-supplements-market

Reasons to get this Report

Key Questions Answered by Gut health supplements Market Report

Strategic Points Covered in Table of Content of worldwide Gut health supplements Market:

Chapter 1: Introduction, market drive product Objective of Study and Research Scope Gut health supplements marketChapter 2: Exclusive Summary the essential information of Gut health supplements Market.Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of Geotextile TubeChapter 4: Presenting Gut health supplements Market correlational analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.Chapter 5: Displaying the by Type, user and Region 2013-2018Chapter 6: Evaluating the leading manufacturers of Gut health supplements market which consists of its CompetitiveLandscape, coevals Analysis, BCG Matrix & Company ProfileChapter 7: to gauged the market by segments, by countries and by manufacturers with revenue share andsales by key countries in these various regions.Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Read the rest here:

Gut health supplements Market Size 2021| Global Statistics, Segmentation with Research and Analysis of Leading Companies - KSU | The Sentinel...

Cannabis-based products have gained increasing recognition in both the medical and wellness sectors in recent years, with the common cannabinoid huge attention among the scientific research community and the general public alike.

CBD, also known by its unabbreviated name Cannabidiol, has become the star ingredient in a baffling range of products in the UK. The retail CBD market has not only grown to include edible products like chocolate, gummies, and drinks, as well as skincare and beauty products but more traditional wellness items such as oil tinctures and capsules.

The CBD used in the production of items such as these is classed by UK and EU regulations as a food supplement. This means that they are moderated by the Food Standards Agency and are not considered, nor should they be labelled as, a medical product.

On the other hand, CBD is also used in medical products such as Epidyolex the use of which is highly controlled with access only permitted through the prescription of a specialist clinician. But what is the difference between these two classes of CBD products?

The success of the CBD industry, both in the UK and in many other countries around the world, has been largely spearheaded by anecdotal evidence in combination with the findings of limited clinical studies. Many users have raved about the products potential to ease anxiety and stress, aid in sleep, and even help with pain and muscle recovery.

While anecdotal evidence is relatively strong in this respect, there are few clinical studies to back up the perceived benefits of CBD. Research into the cannabinoid is on the rise, however, it is important to note that these trials are carried out with carefully controlled cannabis extracts at much higher doses than you would get in high-street products.

While over-the-counter CBD products may well provide individuals with relief from some symptoms such as those previously mentioned, the manufacturers are restricted from making any sort of medical claim. This is because the products have not been subjected to any medical assessment or research. It is also important to remember that CBD affects everyone differently, so while one person may experience impressive relief from CBD products, another might not notice any difference at all!

In contrast to over-the-counter (OTC) CBD products, cannabidiol-based medical products are subjected to a number of manufacturing and licensing standards.

Prior to being approved as a medicine in the EU and UK, pharmaceutical products must pass European Medicines Agency pharmaceutical authorisation. This means that the medicine and pharmaceutical company must be compliant to Good Laboratory Practise, Good Clinical Practise and Good Manufacturing Practise.

In addition, the manufacturers must submit information regarding the product and results of clinical trials for assessment by the European Medicines Agency. These assessments consider the chemical and physical properties of the product, the benefits reported by patient groups and potential risks and side effects associated with the use of the product. Risks and side effects are also continuously monitored following the authorisation of the medicine.

In contrast to pharmaceutical CBD-based products such as Epidyolex, CBD products such as oil tinctures and edibles that are easily available over the counter or on the internet are not subjected to clinical trials or pharmaceutical-grade testing.

Furthermore, while laboratory testing of these products is often available to guarantee the cannabinoid content and ensure that you are getting what you pay for many products available online and in high street shops have been found to be incorrectly labelled in the UK. For example, a study carried out by the Centre for Medicinal Cannabis in June 2019 found that almost half of products tested incorrectly stated the CBD content. One of these products actually contained no cannabidiol at all.

Having said this, it is important to clarify that there is a large number of high-quality, reliable CBD brands currently operating in the UK. Moreover, the incoming Novel Foods deadline for certification in March this year will likely eliminate much of the low-quality brands operating in the sector.

Another of the most significant differences between CBD products bought over the counter and those that are only available through prescription is the strength and recommended dose. A starting dose of Epidyolex, prescribed for the treatment of intractable epilepsy, is 2.5 mg/kg, increasing to 5 mg/kg after one week. For context, each ml of Eidyolex solution contains 100mg of CBD.

In contrast, OTC CBD products often contain much lower levels of cannabidiol that has not been rigorously tested. These products often come with dosing recommendations that dont come close to the doses used for medical purposes.

While a huge number of people may have experienced some positive effects having used OTC CBD products, it is important to remember that they should not be used as an alternative to medicines designed for serious health conditions. Although current research has found that CBD is not harmful at moderate or even high doses, you should not exceed dosage recommendations laid out on each CBD product.

If you are seeking medical help with the use of CBD or other cannabinoids, you should discuss with this with your doctor.

Read more:

What is the Difference Between CBD 'Medicines' and 'Food Supplements'? - The Cannabis Exchange

By partnering with a supplier who understands natural ingredients and the science behind complicated formulations, manufacturers can ensure theyre well equipped to meet any consumer trend now, and into the future. said Michael Baumann, DuPont Nutrition & Biosciences

WILMINGTON, Del. (PRWEB) January 14, 2021

Consumers are increasingly prioritizing dietary supplements to support their immune health, weight management and sleep habits. In a recent industry survey, 95 percent of supplement manufacturers report that consumer interest in the power of nutrition to boost health and wellness and support immunity has never been higher (1). Manufacturers seeking to grow their business with this increased demand can turn to DuPont Nutrition & Biosciences' (DuPont) expanded dietary supplement ingredient portfolio and newly launched website, equipped to help them develop high-quality, efficacious formulations.

Backed by decades of technical expertise, DuPonts sustainably-sourced and plant-based ingredient portfolio is tailored to tackle the toughest formulation challenges, from taste-masking bitter botanicals, to delivering convenient new formats to keeping up with consumers evolving preferences and lifestyles. With a finger on the pulse of the industry, DuPont stands poised to help manufacturers grow their business based on survey results that indicate:

Manufacturers can discover these innovative offerings and more on DuPonts new dietary supplement ingredients website. Serving as a robust, holistic hub, customers can refine their search based on their individualized needs by product, solution or delivery formats and explore how by leveraging DuPonts comprehensive and unique portfolio they can turn natural sources into shelf-ready products, in a variety of application forms.

As the dietary supplement industry expands at a dizzying rate, were leveraging our pharmaceutical expertise, as well as our market and industry insights, to equip supplement manufacturers with the innovations they need to stay one step ahead, said Michael Baumann, global strategic marketing manager, DuPont Nutrition & Biosciences. By partnering with a supplier who understands natural ingredients and the science behind complicated formulations, manufacturers can ensure theyre well equipped to meet any consumer trend now, and into the future.

Dedicated to ongoing collaboration with supplements manufacturers, DuPont will demonstrate how formulators can create great-tasting, low-sugar gummy supplements while also increasing speed to market in an upcoming webinar Hydrocolloids: How a Small Part of your Formulation can have a Big Impact on Gummy Success. Hosted by NutraIngredients, the webinar will take place January 28, at 11:00 AM EST. To register, visit https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=95D7EF8B-D362-4EBB-B056-A2D4D031B94B/

To learn more about DuPont Nutrition & Biosciences dietary supplements ingredients portfolio or expertise areas, visit dietarysupplements.dupont.com.

1 NutraIngredients, USA State of the Industry Survey 20202 Ibid*Please note that regional differences in applicable laws and regulations may restrict the use of certain products in dietary supplements or different terminology definitions may apply.

About DuPont Nutrition & Biosciences DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com

About DuPont DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com/. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

1/14/2021DuPont, the DuPont Oval Logo, and all trademarks and service marks denoted with , SM or are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

Share article on social media or email:

See original here:

Dietary Supplement Ingredient Initiatives Bolster Industry Amid Increased Growth - PR Web

It is clear that cannabidiol (CBD) is everywhere and in (almost) everything; in foods, beverages, and even pet foods. What is less clear is how CBD ranks as an enforcement priority for the U.S. Food and Drug Administration (FDA") and what the agency expects of manufacturers.

Even though FDA has previously not objected to the use of certain hemp ingredients in foods that are Generally Recognized as Safe (GRAS) by the agency (e.g., hulled hemp seed, hemp seed protein powder, and hemp seed oil), its official position on CBD, which is derived from hemp, is that CBD cannot be sold as a dietary supplement or added to food. This position has not stopped food and supplement companies, however, from continuing to produce and market CBD products.

Most marketers of CBD products have avoided FDA enforcement so far. But any company that claims its CBD product can treat a disease or ailment is at risk of facing enforcement action from FDA, the Federal Trade Commission (FTC), or, in some cases, both agencies. FDA continues to monitor the CBD marketplace for potentially dangerous products, issuing warning letters in December of 2020 to five companies. Notably, FDA identified concerns about high-risk routes of administration (including nasal, ophthalmic, and inhalation) for the products at issue. Although FDA is the primary U.S. regulatory authority with respect to foods and dietary supplements, FTC recently announced its first law enforcement crackdown on deceptive claims in the growing market for CBD products. The FTC took action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimers disease, and other conditions. Some believe that FDA will remain focused on developing underlying policies related to the use of CBD in consumer products, while FTC will now more aggressively pursue companies that make aggressive claims that CBD can be used to treat serious diseases.

Although FDA has repeatedly clarified that CBD cannot be added to foods and dietary supplements, its enforcement thus far has been limited to the highest-risk violators, such as CBD products that claim to prevent, diagnose, treat, or cure serious diseases. This type of enforcement is not unique to CBD products, as FDA often issues warning letters to manufacturers of supplements or foods bearing similar claims. However, if FDA treats CBD in functionally the same way as it enforces its regulations for supplements or foods, the CBD industry is left to contemplate important questions: Where does FDA actually draw the line when it comes to CBD products? Does it even matter?

A highly anticipated policy initiative may answer this question. In July 2020, FDA submitted a guidance document outlining its CBD enforcement discretion policy, "Cannabidiol Enforcement Policy; Draft Guidance for Industry," (the Guidance") to the Office of Management and Budget (OMB) for review. Since FDAs submission of the Guidance, industry has been eagerly awaiting further updates. However, the Guidance has been pending since July 22, 2020, and as of December 17, 2020, still has not been cleared. On December 8th, in a Fireside Chat with Haynes and Boones Suzie Trigg, Joseph Franklin, Policy Director for the Principal Deputy Commissioner at FDA, noted that The only thing that we can say, from the FDA perspective, is that it was submitted in July for OMB review as part of the normal process. Thats the only comment we can provide on that at this time.

Historically, FDA's formal enforcement discretion policies outline requirements that regulated industry must meet to avoid FDA enforcement. These guidance documents encourage voluntary compliance while concurrently allowing the agency to allocate its limited enforcement resources to higher-priority initiatives. Publishing an enforcement discretion policy for CBD would formalize FDA's existing practice of primarily targeting high-risk violators while shining light on other factors it considers when making enforcement decisions. As seen from FDA's use of similar enforcement policies for personal protective equipment during the COVID-19 pandemic, providing clarity to industry through guidance assists companies who wish to comply by providing practical guidance. The practice also acknowledges the reality that FDA does not have the resources to closely monitor all products under its jurisdiction. Companies that choose to operate outside the scope of such enforcement discretion policies risk inviting avoidable enforcement actions from FDA.

The protracted pace of review for the Guidance may soon speed up with a new administration set to take over in January, but there are also other policy initiatives that could alter the regulation of CBD. Congressional action is one possibility, given previous bipartisan interest in developing a legal pathway for CBD. CBD received a mention in the 2020 Consolidated Appropriations Act, with the Explanatory Statement encouraging additional NIH research on CBDs therapeutic effects and toxicity and recommending that $2 million be devoted to FDAs CBD activities. Also in 2019, a bipartisan group of legislators submitted a letter to FDA requesting a formal enforcement discretion policy and an interim final rule outlining how CBD could be marketed as a dietary supplement and food additive. It is likely that this letter may have served as the impetus for the currently-pending Guidance, even though it is unclear whether FDA is considering the issuance of an interim final rule at this time.

Another piece of legislation under consideration, the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020, was introduced in September 2020 and would explicitly declare CBD and other hemp derivatives to be dietary ingredients, thus rendering them eligible to be added to dietary supplements. As a dietary ingredient in supplements, CBD would also be subject to the applicable supplement regulatory requirements, such as compliance with Good Manufacturing Practices and labeling requirements. The bill is still in committee, but has generally been viewed positively by industry as a clear path forward for marketing CBD products and ensuring that they are produced and marketed safely.

Additionally, with the CBD industry rapidly maturing, there is always the possibility that a manufacturer could successfully submit a New Dietary Ingredient Notification to FDA in 2021 without objections, opening the door for FDA to at least indirectly acknowledge the safety of CBD in dietary supplements.

Still, the need for regulatory guidance is greater than ever, especially with the uncertainty at the federal level further complicated by a patchwork of wide-rangingand sometimes conflictingstate regulatory schemes. With an assortment of requirements to choose from, how should a CBD company market its products to minimize enforcement risks? There are a few key standards to always keep in mind:

Until FDA provides greater clarity, the CBD industry may continue to grow in response to consumer demand. However, one thing is clear: marketing foods and supplements containing CBD is still a risk, and using health or disease claims to market a CBD product is a surefire way to attract the attention of FDA and FTC.

Read this article:

Is 2021 the Year for Federal Movement on CBD? - Lexology

DSMs recent global survey of 12,000 people found that supporting immunity remains a top health priority for consumers worldwide, with65% of consumers currently worried about immunity and 70% consuming supplements to support their immune system (DSM Consumer Immunity Panel, September 2020).

To help solve this concern, DSM has developed a 'fast-acting' form of vitamin D3 named 'ampli-D' (aka calcifediol).

The development comes in response to a growing portfolio of evidencelinking vitamin D with COVID-19 symptom severity.

This fast building body of research, and the the fact that a large proportion of the global population needs supplementation during the winter due to low exposure to sunlight, have led to high consumer demand for the vitamin.

However, DSM says it can take months to bring the body to optimum sufficiency using some Vitamin D2 and D3 supplements.

Calcifediol (25-hydroxyvitamin D3) is another form of vitamin D naturally present in food sources like fish, milk and eggs and it isthe most common form of vitamin D in our body.

Research has found this form of the vitamin as a supplement is three to five times more efficient than vitamin D3 (cholecalciferol)and that it has a higher rate of intestinal absorption and thereby canimprove vitamin D status in days to weeks.

Peter Van Dael.Senior Vice President of Nutrition Science & Advocacy at DSM, says the ability to raise vitamin D levels quickly is more important than ever, helping to support peoples immunity during the current global pandemic as fast as possible.

Although current practices such as vaccinations, hygiene measures, wearing face masks, and social distancing are still extremely important in limiting the spread of viral infections, like the highly contagious COVID-19 disease caused by the SARS-CoV-2 virus, additional focus on the role of nutrition and its positive impact on immunity is also critical.

"Given the supporting evidence, nutritional supplementation is strongly advised as part of future public health strategies. Complementing a healthy, balanced diet with a nutritional supplement like vitamin D, preferably calcifediol is a safe, effective and low-cost way to support healthier futures across the world, as it helps to promote an optimal immune response and manage the risk and severity of infectious diseases.

The new product will soon be available in Australia, with other global markets to follow over the course of 2021.

Continued here:

DSM responds to immunity demands with fast acting vitamin D - NutraIngredients.com

1. Introduction1.1 What the policy is

The government will provide a free 4-month supply of daily vitamin D supplements for residents in residential and nursing care homes in England to help support their general health, in particular bone and muscle health. Each daily supplement will contain 10 micrograms (400 international units (IU)) of vitamin D. This one-off 4-month supply will be delivered directly to residential and nursing care homes from January 2021.

Vitamin D helps regulate the amount of calcium and phosphate in the body. These nutrients are needed for healthy bones, teeth and muscles. Too little vitamin D can lead to bone pain and muscle weakness in adults, which may also increase the risk of falls in older people. The NHS provides general advice on vitamin D.

From around late March and early April to the end of September, most people should be able to get the vitamin D they need from sunlight as the body creates vitamin D from direct sunlight on the skin when outdoors, however during the autumn and winter we cannot make sufficient vitamin D from sunlight. Vitamin D is also found in a small number of foods, such as oily fish and liver, and some fortified foods, such as fat spreads and breakfast cereals; however, it is difficult to get enough vitamin D from food alone.

Therefore, during the autumn and winter months everyone is advised to take a 10 microgram (400 IU) supplement of vitamin D every day.

Some adults are advised to take a daily supplement containing 10 micrograms (400 IU) of vitamin D throughout the year if they are not often outdoors, for example if they are frail, housebound or living in a care home[footnote 1]. Public Health Englands (PHE) guidance on Healthier and more sustainable catering: nutrition principles also includes this recommendation. This advice is particularly important for people who have been shielding this year due to coronavirus (COVID-19), or residents who are living in care homes, because they are more likely to have been indoors over the spring and summer and so may not have been able to obtain enough vitamin D from sunlight. DHSC has therefore prioritised the provision of free vitamin D supplements to people in these groups in England.

Care home providers are required to meet residents full nutritional needs to sustain life and good health, and reduce the risks of malnutrition, in line with regulation 14 (Part A) of the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014. In addition to provision of nutritious meals, this should include food supplements where necessary, such as vitamin D.

This year, the government will provide all nursing and residential care homes in England with a free 4-month supply of vitamin D supplements as it is likely that care home residents will have stayed indoors more than usual over spring and summer last year as a result of the national restrictions for COVID-19.

Care home providers should give residents the choice and offer the four-month supply of vitamin D supplements as part of this nutritional and hydration requirement and in line with existing procedures regarding consent and any relevant safety considerations outlined in section 2.1. All care home providers will need to record provision of vitamin D supplements and can choose the most appropriate way for their care home to do this, in line with section 3.3.

While some care homes may already support residents to take vitamin D supplements, this may be new for other care home providers and members of staff. This guidance has been produced in consultation with the Care Quality Commission to support care home providers to put the appropriate measures in place.

Where residents require support to take a supplement, care home providers must be assured that care staff are trained and competent.

Each daily supplement will contain 10 micrograms (400 IU) of vitamin D. The vitamin D supplement provided will be in a liquid form and 2 drops is equivalent to 10 micrograms.

The vitamin D supplements provided are a food supplement and are not a prescribed medicine. The supplements provided are equivalent to those that are readily available in retail outlets such as supermarkets, pharmacies and health food shops.

This section outlines the safety information that care home providers will need to check prior to offering the vitamin D supplement to residents and provides guidance on the steps that care providers should follow for each resident.

This section also outlines how to offer vitamin D supplements and further information on consent.

There is minimal risk associated with provision of a daily 10 microgram vitamin D supplement. However, there are some rare instances where it should not be offered without having received further advice.

Before offering vitamin D supplements to care home residents, care home providers must read the sections 2.1, 2.2 and 2.3.

Care home providers must check each residents care plan and medicines administration record (MAR) to see if any of the information outlined in sections 2.1.1, 2.1.2, 2.1.3 and 2.1.4 applies to the resident. Care home providers should follow the guidance below on the appropriate steps that should be taken for each resident.

If care home providers do not have sufficient access to a residents MAR or medical conditions, they should check with the residents healthcare professional at their next appointment before offering vitamin D supplements.

Care staff should check each residents care plan and MAR to see whether they are already taking, or are prescribed, a supplement or medicine containing vitamin D by their GP or healthcare professional, for example either cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2), either alone or in combination with other products for example, calcium.

If a GP or healthcare professional has recommended that a resident takes a different amount of vitamin D, their advice should be followed.

Care staff may wish to explain to the resident why they are not being offered an additional supplement.

If the care home manager is unsure about whether the resident already takes or is prescribed a form of vitamin D, further advice should be sought from the residents GP or healthcare professional at the residents next appointment, before offering the supplement. It is not necessary to contact the residents GP or healthcare professional about the vitamin D supplements prior to their next appointment.

Some residents may have medical conditions that mean that they may not be able to safely take as much vitamin D as the general population. Care home providers must check if any of the following medical conditions appear on a residents care plan or MAR:

those under the care of a renal, endocrinology or cancer specialist

people with high vitamin D levels

people with kidney stones(now or in the past)

people with too much parathyroid hormone(hyperparathyroidism),

people with cancer (some cancers can lead to high calcium levels)

people with severe kidney disease

people with a rare illness calledsarcoidosis

Care staff may wish to explain to the resident why they are not being offered the supplement.

If a resident has any of the medical conditions listed above or if the care home manager is unsure whether the resident has any of the medical conditions listed above, further advice should be sought from the residents GP or healthcare professional at the residents next appointment, before offering the supplement. It is not necessary to contact the residents GP or healthcare professional about the vitamin D supplements prior to their next appointment.

Vitamin D supplements are usually well tolerated. Care providers should check the residents care plan and MAR for any allergies. In the rare event of any adverse reactions to the vitamin D supplements, care providers should follow the guidance outlined in section 3.6.

Care staff may wish to explain to the resident why they are not being offered the supplement.

If a resident has an allergy to any of the listed ingredients or if the care home manager is unsure, further advice should be sought from the residents GP or healthcare professional at the residents next appointment, before offering the supplement. It is not necessary to contact the residents GP or healthcare professional about the vitamin D supplements prior to their next appointment.

Some residents may receive clinical care for swallowing difficulties and/or have specific dietary needs met through nutrition support such as a tube feed.

The vitamin D supplements provided will be in a liquid form, however further advice should be sought from appropriate healthcare professionals such as their GP, dietician, pharmacist or speech and language therapist at the next appointment or opportunity, before offering the supplement. It is not necessary to contact the appropriate healthcare professional about vitamin D supplements prior to the residents next appointment.

Care home staff may wish to explain to the resident that they are not being offered the supplement until further advice is sought with the appropriate healthcare professional to confirm whether they can safely take a vitamin D supplement.

While some medicines may interact with high doses of vitamin D, there are unlikely to be any interactions associated with the 10 microgram (400 IU) vitamin D supplement. These supplements are intended to supplement the diet and should not be a substitute for a varied diet.

As outlined in section 2.1.1, if the resident is already taking, or is prescribed, a medication that contains vitamin D by their GP or healthcare professional, they should not be offered the vitamin D supplement.

Care staff must only provide vitamin D to residents when they have provided informed consent, or on the basis of a best interest decision under the Mental Capacity Act 2005 (MCA).

All residents who are able to give informed consent are required to do so, in order to receive the vitamin D supplements. This consent should be recorded in line with existing policy in the home.

In order to take a decision about the provision of vitamin D supplements, care staff should start from a presumption of mental capacity. A resident who has capacity to make their own decision about taking the supplements must be able to understand, retain, use or weigh, and communicate the purpose of the supplements, and, the consequences of taking, or not taking the supplements, and of not making a decision about taking the supplements.

To give informed consent on whether to take the vitamin D supplements, residents need to be provided with information about the risks and benefits of taking vitamin D. This information is outlined in section 1 of this document which can be used by care home providers to help residents make an informed decision (and to assess if they have relevant mental capacity to take the decision, or not (more below).

Some residents may lack mental capacity to consent to take the supply of vitamin D supplements. A person aged 16 or over is protected by the empowering, decision-making framework set out under the Mental Capacity Act 2005 (MCA).

Residential and nursing care homes will have established processes for assessing a residents mental capacity to take specific decision at a specific time, and for taking a best interests decision if they do not have relevant capacity. Care home providers should follow their existing MCA and best interests decisions procedures and keep a record of decisions relating to vitamin D supplements in line with the MCA Code of Practice.

Where it has been established that the resident lacks capacity to consent to taking a vitamin D supplement, a best interests decision should be taken in line with the best interest checklist in section 4 of the MCA. This means that the decision-maker must consider all the relevant circumstances, including the likely health benefits to the resident, the residents wishes, beliefs and values, the views of their family and what the resident would have wanted if they had the capacity to make the decision themselves. The decision maker should make a record of this decision in line with existing policy in the home. Best interests decisions should be made on an individual basis.

Where appropriate, the residents advocates or those with power of attorney for Health and Welfare should be consulted. If there is a deputy or attorney with relevant authority then consent must be sought from them to be able to provide the supplements. Such consent can only be provided if it is in the persons best interests.

Provision of vitamin D supplements should be person-centred and care home providers should incorporate vitamin D supplement provision into existing routines and care plans which are designed to meet the nutritional and hydration needs of individual residents.

One daily dose of the vitamin D supplement should be offered to residents who it is suitable for in line with section 2.1, and where choice and consent has been provided in line with section 2.3.

Two drops of the liquid vitamin D supplement make up one daily dose which is equivalent to 10 micrograms of vitamin D. This is equivalent to 400 IU of vitamin D.

Residents should not exceed the recommended dose (1 dose per day containing 10 micrograms equivalent to 400 IU). This is the amount designed to meet their nutritional needs. Taking more is not currently recommended. More information on this is in section 3.5.

There should be individual person-centred care planning and this should ensure that the supplements are provided to the residents at the most suitable time for the individual person. You may wish to record the name of each resident on the packaging of their individual supply of the vitamin D supplement.

Timings of the supplement provision will vary from person to person. Care home providers must comply with the instructions set out on the product label.

Residents care plans should be updated to reflect whether they will be provided with a daily vitamin D supplement and how they will be supported to take it.

Care home managers, or staff with the relevant authority should record on a daily basis, whether a vitamin D supplement has been provided and taken by a resident as part of their daily care routine. Care home providers can choose where to record the provision of vitamin D supplements, so it aligns with their existing processes and it is the least burdensome approach. For example, this could include a MAR, daily notes or nutrition or dietary records.

If residents are deemed able and competent and wish to self-administer their supplements, they should be supported in doing so. A resident who self-administers should have a current risk assessment in place including safe storage. Supervision and support should be provided if a self-administration risk assessment has deemed it to be necessary.

Care home staff are advised to only give one dose of vitamin D supplement a day and record it. If there is any deviation from this, it should be recorded appropriately.

If an error has taken place, it should be identified, reported, reviewed and learnt from to reduce the likelihood of reoccurrence. This may include additional staff training, competency checks, updates to policies and care plans.

If there are concerns that the error puts the resident at risk of abuse or neglect (a safeguarding issue), local safeguarding procedures should be followed.

For most adults taking up to 100 micrograms (equivalent to 4,000 IU) per day is considered safe. In a few people, taking too many vitamin D supplements over a long period of time can cause too much calcium to build up in the body (hypercalcaemia). This can weaken the bones and damage the kidneys and the heart. The NHS has more information about vitamin D, including advice on safe intakes.

The 100 microgram daily tolerable safe level of intake is set on the basis of long-term studies. The Food Standards Agency emphasise that evidence on acute toxicity is limited particularly for those with complicated health conditions.

In the rare event of any adverse reactions to the vitamin D supplement, discuss with the residents GP, pharmacist or other healthcare professional. Severe adverse reactions must be reported to the GP immediately. In the rare event that a serious life-threatening allergic reaction or severe adverse reaction takes place, the care home staff must dial 999 for urgent medical attention from the emergency services and administer first aid as required.

The care provider should store the supplements securely at the correct temperature with access restricted to authorised staff. Care home providers must comply with the instructions set out on the product label.

View post:

Vitamin D and care homes guidance - GOV.UK - GOV.UK

Profiling Key Players: AMWAY, General Nutrition Centers, Inc., Puritans Pride, Pharmavite, Jamieson, Webber Naturals, Pfizer Inc., Daiichi Sankyo, Eisai, Salus-Haus, DSM, Hainan Yangshengtang, CSPC Pharmaceutical Group, Sanofi China

The vitamins and mineral supplements market consists of sales of vitamins and mineral supplements that improve the health and wellness of the population. The sales comprise of revenue generated by the establishments manufacturing vitamins and minerals. Vitamins and mineral supplements are available without a prescription and come in tablets, powders or liquids and provide sufficient vital nutrients and minerals that preserve or boost an individual`s health. The vitamins and mineral supplements market covered in this report is segmented by type into multivitamin, single vitamin, multi mineral, single mineral. It is also segmented by application into energy & weight management, general health, bone & joint health, gastrointestinal health, immunity, cardiac health, diabetes, anti-cancer, others, by distribution channel into pharmacies & drug stores, supermarkets & hypermarkets, online channels, and by end-user into adults, geriatric, pregnant women, children, infants.

Get Pdf Sample Copy of thisReport@https://www.marketresearchinc.com/request-sample.php?id=55644

The growing use of dietary supplements in the modern lifestyle is a key factor driving the growth of the vitamins and mineral supplement market. Nutrition plays an important role in maintaining immune system balance, and supplementation with the micronutrients such as vitamins C and D, Zinc and omega fatty acids within recommended upper safety limits is a safe, effective and low-cost strategy to help support optimal immune function in patients fighting COVID-19 and other respiratory tract diseases. In the case of COVID 19 patients, a variety of high-protein and fibre foods, including cookies, bread and rolls, have been developed by the Indian Research Institute. For example, to improve children`s immunity, dietary supplement company Avida Health has launched a chocolate ball functional food in Singapore. A nutritional focus on the immune system could help minimize the impact of the current COVID-19 pandemic and other infections. Therefore, the implementation of dietary supplements in the lifestyle is expected to drive the growth of the vitamins and mineral supplement market.

Highlighted key points of this market research report:

Get Maximum Discount Now @ https://www.marketresearchinc.com/ask-for-discount.php?id=55644

Market by Channel Type Application:

Different top-level key players are also enlisted in order to obtain in-depth knowledge and informative data of companies. Some of the key players are also profiled in this research report, which includesVitamin and Mineral SupplementMarket. Different industry analysis tools such as SWOT and Porters five-technique are further used while analyzing the globalVitamin and Mineral SupplementMarket.

For more Inquiry detailed TOC of Research Report:https://www.marketresearchinc.com/enquiry-before-buying.php?id=55644

Table of Content:

Chapter 1:Vitamin and Mineral Supplement Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Vitamin and Mineral Supplement Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Vitamin and Mineral Supplement Market Effect Factors Analysis

Chapter 12: GlobalVitamin and Mineral Supplement Market Forecast to 2025

About Us:Market Research Inc is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

Contact Us:AuthorKevinUS Address:51 Yerba Buena Lane, Ground Suite,Inner Sunset San Francisco, CA 94103, USACall Us: +1 (628) 225 1818Email:sales@marketresearchinc.com

See the original post here:

Global Vitamin and Mineral Supplement Market with Covid-19 Impact Analysis, Top Companies Like Wegmann, Plombco, Toho Kogyo, Statistics, Growth,...

DUBLIN, Jan. 11, 2021 /PRNewswire/ -- The "Immunity Boosting Food Products Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.

Immunity Boosting Food Products Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global immunity boosting food products market.

The global immunity boosting food products market reached a value of nearly $830,302.0 million in 2019, having grown at a compound annual growth rate (CAGR) of 3.8% since 2015, and is expected to grow at a CAGR of 6.2% to nearly to reach $1,056,384.7 million in 2023. The market is expected to grow at a CAGR of 7.6% to nearly $ 1,222,018.0 million by 2025, and at a CAGR of 7.0% to $1,710,772.8 million by 2030.

Growth in the historic period resulted from rise in disposable income and strong economic growth in emerging markets. Factors that negatively affected growth in the historic period were talent crunch and fluctuating prices of raw materials. Going forward, growing number of health-conscious consumers, faster economic growth, growing demand for immunity boosting foods and beverages during covid-19, rising penetration of organized retail and rising population will positively impact the market growth. Factors that could hinder the growth of the immunity boosting food products market in the future include high cost of raw materials and lack of awareness, intense competition and reductions in free trade.

The immunity boosting food products market is segmented by product type into herbs & spices; nuts & seeds; fruits & vegetables; dairy-based products; probiotics and prebiotics; food supplements and others. The nuts & seeds market was the largest segment of the immunity boosting food products market segmented by product type, accounting for 40.2% of the total in 2019. Going forward probiotics and prebiotics segment is expected to be the fastest growing segment in the immunity boosting food products market, at a CAGR of 9.8%.

The immunity boosting food products market is also segmented by form into tablets; capsules; powder; liquid; fresh food; chilled/frozen; canned; dried food and other forms. The dried food market was the largest segment of the immunity boosting food products market segmented by form, accounting for 28.5% of the total in 2019. Going forward liquid segment is expected to be the fastest growing segment in the immunity boosting food products market, at a CAGR of 6.6%.

The immunity boosting food products market is also segmented by distribution channel into store-based and non-store-based. The store-based market was the largest segment of the immunity boosting food products market segmented by distribution channel, accounting for 91.4% of the total in 2019. Going forward non-store-based segment is expected to be the fastest growing segment in the immunity boosting food products market, at a CAGR of 7.8%.

The top opportunities in the immunity boosting food products market segmented by product type will arise in the nuts & seeds market segment, which will gain $76,539.7 million of global annual sales by 2023. The top opportunities in the immunity boosting food products market segmented by form will arise in the dried food segment, which will gain $59,195.2 million of global annual sales by 2023. The top opportunities in the immunity boosting food products market segmented by distribution channel will arise in the store-based segment, which will gain $200,974.5 million of global annual sales by 2023. The immunity boosting food products market size will gain the most in China at $39,747.3 million.

Market-trend-based strategies for the immunity boosting food products market include focusing on probiotic products to leverage growing demand, focusing on instant immunity boosting products, focusing on wellness shots, consider investing in immunity boosting ice creams, focusing on launching immunity boosting beverages and focusing on natural botanicals infused drinks. Player-adopted strategies in the immunity boosting food products industry include developing innovative immunity boosting products, strategic acquisition of emerging and innovative companies, expanding business presence in developing markets, strategic partnerships and joint ventures with established companies and distribution partnerships with existing players.

To take advantage of the opportunities, the publisher recommends that companies should focus on providing wellness shots, immunity boosting beverages and ice-creams, natural botanical infused drinks, adoption of robotics and automation, competitive pricing, premium pricing, expanding in emerging economies, adoption of online delivery services, leverage social media, and targeting mature age groups.

Immunity Boosting Food Products Market Trends and Strategies

Story continues

Yogurt As a Best Source of Probiotics for Immunity during COVID-19

Instant Immunity Boosters

Wellness Shots

Immunity Boosting Ice Creams

Immunity Boosting Beverages

Natural Botanicals Infused Drinks

Companies Mentioned

AlchemLife

Alticor Inc

Amul

Amway India

Amway Japan

Ancient Nutrition

Archer Daniels Midland Company

Associated British Foods plc

Baidyanath Ayurved Bhawan Pvt. Ltd

Bayer AG

Bioextra Co Ltd

BioGaia

Blackmores Limited

Blue Diamond Growers

By-health Co Ltd

Chobani

Conagra Brands, Inc.

Dabur

Danone S.A

Del Monte India

Diamond Foods

Diamond Of California

Dole Food Company, Inc.

Dr. Willmar Schwabe GmbH & Co. KGGoodMills Innovation

DOHLER

Emami

Evalar Company

Fonterra Co-Operative Group Limited

Glanbia Plc

GoodMills Innovation

GSK group of companies

H&H Int'l Hldg

Herbalife Nutrition

Hines Nut Company

House Wellness Foods

Infinitus Company Ltd

ITC

Kerala Ayurveda

Kirin Holdings Company

Marico

Nestle S.A

NOW foods

Nutramax Laboratories

Olam International

Organic India Private Limited

Patanjali Ayurved

Prisum International

Royal DSM

Secom

Strong Nature

Taisho Pharmaceutical

Teijin

The Himalaya Drug Company

USA KOR Shots

USANA Health Sciences

Vive Organic

VLCC Wellscience

ZAND Immunity

Zandu

For more information about this report visit https://www.researchandmarkets.com/r/4hxqdo

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-immunity-boosting-food-products-market-opportunities-and-strategies-report-2020-reveals---yogurt-as-a-best-source-of-probiotics-for-immunity-during-covid-19-301205103.html

SOURCE Research and Markets

Read more:

Global Immunity Boosting Food Products Market Opportunities and Strategies Report 2020 Reveals - Yogurt As a Best Source of Probiotics for Immunity...

In a statement released Friday,FDA commissioner Dr Stephen Hahn and principal deputy commissioner Dr Amy Abernethy noted that while CBD is now widely available, we still have a limited understanding of the safety profile of CBD and many other cannabis-derived compounds."

Specifically, they added: We still dont have clear answers to important questions such as what adverse reactions may be associated with CBD products and what risks are associated with the long-term use of CBD products. Better data in these areas are needed for the FDA and other public health agencies to make informed, science-based decisions that impact public health.

Existing efforts generallyare not adequate to fill the outstanding knowledge gaps, they claimed, noting that longitudinal studies, which provide data about the health of subjects over an extended period of time, are needed to understand long-term health effects of CBD use.

Meanwhile, they added, observational studies that are too small or that do not include techniques to ensure data quality or methodological rigor are of limited use for public health decision making.

Rates of CBD use, and rates of use of specific CBD products, are also poorly understood, they said: What is the denominator of risk for adverse events in the population taking CBD? What specific populations have the highest CBD exposures and what specific products are frequently used? What other products, such as over-the-counter or prescription drugs, are used alongside CBD products? Are there risks associated with interactions between CBD products and other products, beyond those that have already been identified and communicated by the FDA?

So what does this mean for food and supplement companies, who have been operating in a kind of legal grey area for years, navigating a patchwork of different state rules, and waiting for action at a federal level from the FDA, which says ingestible CBD is not a lawful dietary ingredient (because it was first investigated as a drug), but has not pulled it from shelves, instead focusing enforcement action on companies making unsubstantiated health claims?

Steve Mister, president and CEO of Washington DC-based trade association the Council for Responsible Nutrition (CRN), said the latest statement amounted to nothing more than an end-of-administration desk-clearing exercise from an FDA that has failed to lead in this crucial policy area.

Todays announcement tries to excuse the agencys inaction by decrying a lack of data, even as FDA has blocked the New Dietary Ingredient (NDI) route for CBD supplements by declining to review them, and done little that might incentivize data to be presented or invested in research of its own.

The FDA could fix this problem today by simply applying the current regulatory framework for assessing new dietary ingredients to cannabinoids such as CBD, argued Mister, who filed a citizen's petitionlast Juneurging the FDA to regulate CBD as a legal dietary supplement.

And the longer we wait, the longer consumers are potentially at risk, and responsible players in the industry at a disadvantage, he claimed.

Because of the FDAs failure to act, the public continues to be exposed to possible harms by a wild-west market that continues to expand without meaningful regulatory bounds.

"And responsible manufacturers of dietary supplements containing CBD who are dutifully abiding by those regulations, and incurring the costs of doing so suffer as their products are sold alongside products that may or may not contain CBD, may contain THC, make illegal disease claims, or contain unsafe adulterants.

According to the CRN's 2020petition, the"FDA already has explicit authority to promulgate a regulation finding that dietary supplements containing CBD may be lawfully marketed under the FDCA, despite its use first as a drug.Under this path, FDA would, by regulation, remove CBD from the exception to the statutory definition of a dietary supplement that applies to certain articles that were first approved or investigated as a new drug."

After that, each unique manufacturer of a CBD-containing ingredient would then be required to file its own new dietary ingredient notification (NDIN) proving product safety; products would have to be manufactured using good manufacturing practices (GMPs) in FDA-registered facilities; firms would have to follow adverse event reporting requirements, and products would have to be labeled in compliance with FDA regulations.

So what do legal experts make of the FDA's progress report, and what does it mean for food and supplement makers?

Given the exclusionary rule, which prohibits food/supplement makers from using an ingredient that was first investigated as a drug, the FDA nowneeds to prescribe limits and conditions for the inclusion of cannabidiol in dietary supplements, foods and beverages through notice and comment rulemaking,argued Jeni Lamb Rogers, partner atPSL Law Group.

But this will take some much-needed initiative from the FDA, which we have not seen from the agency on cannabidiol to date,"she told FoodNavigator-USA.

In the meantime, she said,The FDAs inaction creates perverse incentives for actors in the marketplace,"byputting responsible players at a disadvantagebecause they face higher compliance costs.

"Consumers have no effective way of distinguishing between products that are produced safely and those that are not.

In the absence of federal regulations, states such as New York, Florida and Colorado, meanwhile, are coming up with their own rules on CBD, she said."I deal with the consequences of this every day in my practice advising clients on how to label cannabidiol products. When you layer in the complexity of myriad and conflicting state laws, manufacturers trying to do the right thing have a hard time clearly communicating all the requirements to the consumers on their labels.

She added:I think the agency will find that if it proposes something to the industry, it will get much of the feedback that it needs regarding safety through the notice and comment process, and once a rule is finalized there will be a legal framework to enforce for the safe production of cannabidiol products as supplements and foods for the betterment of public health.

JosephSchilleci, Jr., attorney and owner atSchilleci & Tortorici, added: "TheFDA continues to state publicly that CBD based supplements are prohibited while products alleged to have CBD included are flooding the marketplace without any guidance from the federal government.

"It would be our view that this trend will continue and only get worse, leaving the States with the unenviable position of having to decide matters on a state-to-state and inconsistent basis while the FDA stands idly by....Nonetheless, it will be interesting to watch in the coming months with a new President and Congress."

Many CBD products'didnot contain the levels of CBD they claimed to contain'

In connection with several warning letters, the FDA said its tests had foundmultiple products currently on the market do not contain the levels of CBD they claimed to contain.

The first phase of the FDAs sampling and analysis study (~200 samples) found thatfewer than half of the tested products contained CBD at concentrations within 20% of their claimed amount and some products contained the psychoactive, intoxicating cannabinoid THC.

The second phase of the sampling plan which has yet to be conducted - will involve a much larger sample set (1,000-3,000 products), said the agency.

Continue reading here:

FDA progress report on CBD 'nothing more than an end-of-Administration desk-clearing exercise,' says CRN - FoodNavigator-USA.com